�����������ƻ��ϵͳ�Ժ���Ǵ���Ч����

Clinical efficacy of mizoribine in treatment of active systemic lupus erythematosus.

??Abstract??Objective To evaluate the efficacy and safety of mizoribine (MZR) for active systemic lupus erythematosus (SLE) in comparison with mycophenolate mofetil (MMF) and cyclophosphamide (CYC).Methods Ninety patients with active SLE were enrolled between April 2012 and March 2013.Thirty patients were given MZR orally at a dose of 300 mg every other day.Thirty patients were taken MMF at 2 g per day in two divided doses.Thirty patients received 0.5 g CYC intravenously every two weeks.Therapeutic effects and adverse events (AEs) were evaluated at the end of 24-week treatment.Results The overall response rates of MZR??MMF and CYC group were 75.86%??78.58%??and 79.31% at week 24 respectively.In MZR??MMF and CYC group??34.48%??39.29%??and 37.93% patients achieved complete remission respectively.There was no significant difference in the overall response rates or complete remission rates among the three groups.SLEDAI scores??24-hour proteinuria and anti-dsDNA titer significantly decreased in all the three groups.All of the three treatments significantly increased leukocyte counts??hemoglobin levels??platelet counts??and serum complement C3 and C4 levels.No significant difference was observed in the parameters above among the three groups.The incidences of AEs in patients treated with MZR or MMF were significantly lower than those in patients treated with CYC.Conclusion MZR is well tolerated and has an effect similar to MMF or CYC in the treatment of active SLE??which may serve as a novel and alternative approach for SLE patients.